Pharmafile Logo

What we do and who we do it for | Pegasus

We’ve built a new type of health communications consultancy. One that believes in a ‘health first, sector second’ approach. One that connects with every stakeholder. One that blends traditional, digital and social. One that creates all of its content in-house. One that’s transparent and measurable.

Why? Because health conversations are happening everywhere, all of the time. Every day we all make decisions that impact on the quality of our own, and often other people’s, health. From the food we eat, the products we put on our skin, the medicines we take or the routines we create to prevent or manage illness. We might be a healthcare professional, a policy maker, a businessman, a patient, a parent or a combination of all these. We could be in a doctor’s surgery, at home, in the gym, or on the go. Whoever we are, wherever we are, and whatever we are doing, the ability to make healthy decisions, consciously or not, will benefit us as individuals and beyond.

This is a new approach to health communications.

This is Pegasus.

Find out more at info@thisispegasus.co.uk or by calling +44 (0) 1273 712 000.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Pegasus’s Approach to Measurement Wins 3 Gold’s at 2014 AMEC International Summit in Amsterdam

Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam

Pegasus Crowned Health Consultancy of the Year at 2014 Sabre Emea Awards

Brighton consultancy adds top honour to its award wins

Pegasus shortlisted for ‘Consultancy of the year’ at 2014 Communique Awards

Brighton-based independent healthcare specialist looks to add award to growing list of accolades

Pegasus Moves to Brighton

Top UK Healthcare Communications Consultancy Moves to Brighton

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.

Patient Power: Too Much of a Good Thing?

Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding